Patients

We retrospectively reviewed 90 consecutive patients with CRPC patients treated with AA from 2011 to 2016, at Yokohama City University Medical Center (Yokohama, Japan), Yokohama City University Graduate School of Medicine (Yokohama, Japan), and National Cancer Center Hospital East (Kashiwa, Japan). All patients were administered 1,000 mg of AA orally once a day and 10 mg oral prednisone daily. Nine patients (10%) had their dose reduced to 500–750 mg of AA because of adverse events. Patients who had active infectious disease or were treated with steroid for any reason and disease before AA initiation were excluded due to influence to NLR. This study was carried out in accordance with the ethical standards of the Declaration of Helsinki. The study was approved by the review boards of each institution: Yokohama City University Medical Center Institutional Review Board (Yokohama, Japan) and National Cancer Center Hospital East Institutional Review Board (Kashiwa, Japan). Due to the fact that the present study was retrospective and observational, the review board waived the requirement for patient informed consent.